VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Informed consent of parent(s) or legal guardian;   │ Informed consent of parent(s) or legal guardian;   │     100 │
│ informed consent or assent of subject as           │ informed consent or assent of subject as           │         │
│ applicable                                         │ applicable                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Male or female children between the ages of 10 and │ Male or female children between the ages of 10 and │     100 │
│ 35 years with congenital heart disease that has    │ 35 years with congenital heart disease that has    │         │
│ been palliated with a Fontan circulation           │ been palliated with a Fontan circulation           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Ability of perform a maximal exercise test as      │ Ability of perform a maximal exercise test as      │     100 │
│ defined by a respiratory exchange ratio (RER)      │ defined by a respiratory exchange ratio (RER)      │         │
│ greater than 1.0 at the time of maximal exercise   │ greater than 1.0 at the time of maximal exercise   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The use of beta blockers within 2 months of        │ The use of beta blockers within 2 months of        │     100 │
│ randomization                                      │ randomization                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients actively listed for transplantation at    │ Patients actively listed for transplantation at    │     100 │
│ time of entry into the study or anticipated to     │ time of entry into the study or anticipated to     │         │
│ undergo heart transplantation, interventional      │ undergo heart transplantation, interventional      │         │
│ catheterization, or corrective cardiac surgery     │ catheterization, or corrective cardiac surgery     │         │
│ during the 7 months following entry into the study │ during the 7 months following entry into the study │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Sustained or symptomatic ventricular dysrhythmias  │ Sustained or symptomatic ventricular dysrhythmias  │     100 │
│ uncontrolled by drug therapy or the use of an      │ uncontrolled by drug therapy or the use of an      │         │
│ implantable defibrillator, and/or significant      │ implantable defibrillator, and/or significant      │         │
│ cardiac conduction defects, e.g., 2nd degree or    │ cardiac conduction defects, e.g., 2nd degree or    │         │
│ 3rd degree AV block, or sick sinus syndrome,       │ 3rd degree AV block, or sick sinus syndrome,       │         │
│ unless a functioning pacemaker is in place         │ unless a functioning pacemaker is in place         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Uncorrected obstructive or severe regurgitant      │ Uncorrected obstructive or severe regurgitant      │     100 │
│ valve disease, nondilated cardiomyopathy, or       │ valve disease, nondilated cardiomyopathy, or       │         │
│ significant systemic ventricular outflow           │ significant systemic ventricular outflow           │         │
│ obstruction                                        │ obstruction                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known renovascular hypertension or evidence of     │ Known renovascular hypertension or evidence of     │     100 │
│ pulmonary hypertension (pulmonary vascular         │ pulmonary hypertension (pulmonary vascular         │         │
│ resistance \> 6 Wood units) unresponsive to        │ resistance > 6 Wood units) unresponsive to         │         │
│ vasodilator agents such as oxygen, nitroprusside,  │ vasodilator agents such as oxygen, nitroprusside,  │         │
│ or nitric oxide                                    │ or nitric oxide                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History or current clinical evidence of moderate-  │ History or current clinical evidence of moderate-  │     100 │
│ to-severe fixed obstructive pulmonary disease or   │ to-severe fixed obstructive pulmonary disease or   │         │
│ severe reactive airway diseases (e.g., asthma)     │ severe reactive airway diseases (e.g., asthma)     │         │
│ requiring hospitalization within the past 2 years  │ requiring hospitalization within the past 2 years  │         │
│ or patient currently using long-term inhaled       │ or patient currently using long-term inhaled       │         │
│ bronchodilators                                    │ bronchodilators                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Renal, hepatic, gastrointestinal, or biliary       │ Renal, hepatic, gastrointestinal, or biliary       │     100 │
│ disorder that could impair absorption, metabolism  │ disorder that could impair absorption, metabolism  │         │
│ or excretion of orally administered medication     │ or excretion of orally administered medication     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Concurrent terminal illness or other severe        │ Concurrent terminal illness or other severe        │     100 │
│ disease (e.g., active neoplasm) or other           │ disease (e.g., active neoplasm) or other           │         │
│ significant laboratory value(s) which, in the      │ significant laboratory value(s) which, in the      │         │
│ opinion of the investigator, could preclude        │ opinion of the investigator, could preclude        │         │
│ participation or survival                          │ participation or survival                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Endocrine disorders such as primary aldosteronism, │ Endocrine disorders such as primary aldosteronism, │     100 │
│ pheochromocytoma, hyper- or hypothyroidism,        │ pheochromocytoma, hyper- or hypothyroidism,        │         │
│ insulin-dependent diabetes mellitus                │ insulin-dependent diabetes mellitus                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Unwillingness or inability to cooperate, or for    │ Unwillingness or inability to cooperate, or for    │     100 │
│ the parents or guardians to give consent, or for   │ the parents or guardians to give consent, or for   │         │
│ the child to give assent, or any condition of      │ the child to give assent, or any condition of      │         │
│ sufficient severity to impair cooperation in the   │ sufficient severity to impair cooperation in the   │         │
│ study                                              │ study                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnancy or possible pregnancy at time of         │ Pregnancy or possible pregnancy at time of         │     100 │
│ randomization, or female of child bearing          │ randomization, or female of child bearing          │         │
│ potential who are lactating, or sexually active    │ potential who are lactating, or sexually active    │         │
│ and not taking adequate contraceptive precautions  │ and not taking adequate contraceptive precautions  │         │
│ (e.g., intrauterine device or oral contraceptives  │ (e.g., intrauterine device or oral contraceptives  │         │
│ for 3 months prior to entry into the study)        │ for 3 months prior to entry into the study)        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of an investigational drug within 30 days of   │ Use of an investigational drug within 30 days of   │     100 │
│ randomization, or within 5 half-lives of the       │ randomization, or within 5 half-lives of the       │         │
│ investigational drug (the longer period will       │ investigational drug (the longer period will       │         │
│ apply)                                             │ apply)                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of any of the following medications within two │ Use of any of the following medications within two │     100 │
│ weeks of randomization: MAO inhibitors, Calcium    │ weeks of randomization: MAO inhibitors, Calcium    │         │
│ channel blockers, alpha blockers, beta blockers,   │ channel blockers, alpha blockers, beta blockers,   │         │
│ disopyramide, flecainide, encainide, moricizine,   │ disopyramide, flecainide, encainide, moricizine,   │         │
│ propafenone, sotalol, or beta adrenergic agonists  │ propafenone, sotalol, or beta adrenergic agonists  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hospital admission for protein losing enteropathy  │ Hospital admission for protein losing enteropathy  │     100 │
│ or plastic bronchitis within 3 months of           │ or plastic bronchitis within 3 months of           │         │
│ randomization                                      │ randomization                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active and/or chronic protein losing enteropathy   │ Active and/or chronic protein losing enteropathy   │     100 │
│ or plastic bronchitis (on inhaled medication to    │ or plastic bronchitis (on inhaled medication to    │         │
│ control the plastic bronchitis)                    │ control the plastic bronchitis)                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hepatic dysfunction defined as serum AST and/or    │ Hepatic dysfunction defined as serum AST and/or    │     100 │
│ ALT\> 3 times upper limit of normal (approximately │ ALT> 3 times upper limit of normal (approximately  │         │
│ 120 IU/L however, will vary depending on age)      │ 120 IU/L however, will vary depending on age)      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of drug sensitivity or allergic reaction   │ History of drug sensitivity or allergic reaction   │      97 │
│ to alpha-blockers or ß-blockers                    │ to alpha-blockers or beta-blockers                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hypoalbuminemia defined as serum albumin \<2.0g/dL │ Hypoalbuminemia defined as serum albumin <2.0g/dL  │      99 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Renal dysfunction defined as serum creatinine      │ Renal dysfunction defined as serum creatinine      │      99 │
│ \>2.0mg/dL                                         │ >2.0mg/dL                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Significant anemia or polycythemia defined as      │ Significant anemia or polycythemia defined as      │      99 │
│ hemoglobin \>18gm/dL or hemoglobin \<7gm/dL        │ hemoglobin >18gm/dL or hemoglobin <7gm/dL          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severely elevated serum BNP defined as             │ Severely elevated serum BNP defined as             │      99 │
│ BNP\>300pg/ml                                      │ BNP>300pg/ml                                       │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                    │   Score │
╞═══════════════════════════════════╪══════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 10 Years │ History of drug sensitivity or allergic reaction │      33 │
│                                   │ to alpha-blockers or beta-blockers               │         │
├───────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 35 Years │ History of drug sensitivity or allergic reaction │      33 │
│                                   │ to alpha-blockers or beta-blockers               │         │
╘═══════════════════════════════════╧══════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 94.57692307692308
OverAll Ratio: 96.78846153846155
